Core Scientific, Inc. Fundamental Analysis (NASDAQ: CORZ)
Core Scientific, Inc. Fundamental Analysis (NASDAQ: CORZ)
Core Scientific, Inc. (NASDAQ: CORZ) shows weak financial fundamentals with a PE ratio of -49.34, profit margin of -18.62%, and ROE of 7.63%. The company generates $0.6B in annual revenue with weak year-over-year growth of -37.53%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 13.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CORZ's fundamental strength across five key dimensions:
Efficiency Score
WeakCORZ struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCORZ trades at attractive valuation levels.
Growth Score
ModerateCORZ shows steady but slowing expansion.
Financial Health Score
ModerateCORZ shows balanced financial health with some risks.
Profitability Score
WeakCORZ struggles to sustain strong margins.
Key Financial Metrics
Is CORZ Expensive or Cheap?
P/E Ratio
CORZ trades at -49.34 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CORZ's PEG of -0.08 indicates potential undervaluation.
Price to Book
The market values Core Scientific, Inc. at -4.29 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -11.16 times EBITDA. This is generally considered low.
How Well Does CORZ Make Money?
Net Profit Margin
For every $100 in sales, Core Scientific, Inc. keeps $-18.62 as profit after all expenses.
Operating Margin
Core operations generate -1.78 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.63 in profit for every $100 of shareholder equity.
ROA
Core Scientific, Inc. generates $-1.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Core Scientific, Inc. generates strong operating cash flow of $441.82M, reflecting robust business health.
Free Cash Flow
Core Scientific, Inc. generates weak or negative free cash flow of $-1.30B, restricting financial flexibility.
FCF Per Share
Each share generates $-4.03 in free cash annually.
FCF Yield
CORZ converts -28.36% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-49.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
-4.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.79
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-4.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.67
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How CORZ Stacks Against Its Sector Peers
| Metric | CORZ Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -49.34 | 32.70 | Better (Cheaper) |
| ROE | 7.63% | 758.00% | Weak |
| Net Margin | -18.62% | -4312.00% (disorted) | Weak |
| Debt/Equity | -4.04 | 0.96 | Strong (Low Leverage) |
| Current Ratio | 0.67 | 12.15 | Weak Liquidity |
| ROA | -1.86% | 1067467.00% | Weak |
CORZ outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Core Scientific, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
531.63%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
-2723.93%
Industry Style: Growth, Innovation, High Beta
DecliningFCF CAGR
1498.31%
Industry Style: Growth, Innovation, High Beta
High Growth